Generation of B2M bi-allelic knockout human induced pluripotent stem cells (MUSIi001-A-1) using a CRISPR/Cas9 system

Nontaphat Thongsin; Methichit Wattanapanitch

doi:10.1016/j.scr.2021.102551

Generation of B2M bi-allelic knockout human induced pluripotent stem cells (MUSIi001-A-1) using a CRISPR/Cas9 system

Stem Cell Res. 2021 Oct:56:102551. doi: 10.1016/j.scr.2021.102551. Epub 2021 Sep 30.

Authors

Nontaphat Thongsin¹, Methichit Wattanapanitch²

Affiliations

¹ Siriraj Center for Regenerative Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
² Siriraj Center for Regenerative Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

PMID: 34628247
DOI: 10.1016/j.scr.2021.102551

Abstract

Allogeneic cell-based therapy is emerging as a promising approach in regenerative medicine. However, rejection of allograft due to mismatch of human leukocyte antigens (HLAs) remains a major concern after transplantation. Here, we generated a homozygous B2M knockout induced pluripotent stem cell (iPSC) line, lacking the expression of HLA class I (HLA-I) molecules, using a CRISPR/Cas9 system. The established iPSC line, MUSIi001-A-1, can serve as an in vitro model for studying immunological responses against allogeneic grafts and provides a prototype for "off-the-shelf" allogeneic cell products for future cell-based therapy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

CRISPR-Cas Systems / genetics
HLA Antigens
Humans
Induced Pluripotent Stem Cells*
Regenerative Medicine
Transplantation, Homologous
beta 2-Microglobulin* / genetics

Substances

B2M protein, human
HLA Antigens
beta 2-Microglobulin